The studies had to involve adults aged 18 and above diagnosed with type 2 diabetes mellitus and examine the cardiovascular effects of GLP-1 RAs or dual GLP-1/GIP therapies. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.